

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
PAULS, et al.

Examiner: JOHNSON, Jason H.

Art Unit: 1623

**RECEIVED
CENTRAL FAX CENTER**

Application No.: 10/616,141

FEB 06 2006

Filed: 07/08/2003

Title: 1-AROYL-PIPERIDINYL BENZAMIDINES

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit

Signature

2-6-06

*Red***INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

BEST AVAILABLE COPY

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,

February 6, 2006



Julie Anne Knight, Reg. No. 48,867
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626
sanofi-aventis Docket No. USA3676 US CNT

COPY
IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
PAULS, et al.

Examiner: JOHNSEN, Jason H.

Application No.: 10/616,141

Art Unit: 1623

RECEIVED
CENTRAL FAX CENTER

Filed: 07/08/2003

FEB 06 2006

Title: 1-AROYL-PIPERIDINYL BENZAMIDINES

Certificate of Mailing or Transmission	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop Amendment address below, or being facsimile transmitted to the USPTO, on the date indicated below.	
Date of Deposit	February 3, 2006
Printed Name of Person Signing Certificate	Denise McGinnis
Signature	<i>Denise McGinnis</i>


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIREDMail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

February 3, 2006


Julie Anne Knight, Reg. No. 48,867
Attorney/Agent for Applicantsanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3744
Telefax (908) 231-2626

sanofi-aventis Docket No. USA3676 US CNT

Please type a plus sign (+) inside this box → ☒PTO/SB/088 (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/616,141
		Filing Date	07/08/2003
		First Named Inventor	PAULS, et al.
		Group Art Unit	1623
		Examiner Name	JOHNSEN, Jason H.
		Attorney Docket Number	USA3876 - US - CNT
Sheet	2	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BEIL, W., et al., Phenotypic and Functional Characterization of Mast Cells Derived from Renal Tumor Tissues, Experimental Hematology Vol. 26, 1998, pages 158-169	
		BISCHOFF, S C., et al., Quantitative Assessment of Intestinal Eosinophils and Mast Cells in Inflammatory Bowel Disease, Histopathology 1996, Vol. 28, pages 1-13	
		BROERSMA, et al., The Effect Of Thrombin Inhibition In a Rat Arterial Thrombosis Model, Thrombosis Research 64; 405-412, 1991	
		BUCKLEY, M., et al., Mast Cell Subpopulations in the Synovial Tissue of Patients with Osteoarthritis: Selective Increase in Numbers of Tryptase-positive, Chymase-negative Mast Cells, Journal of Pathology, Vol. 186, 1998, pages 67-74	
		CAIRNS, et al., Mast Cell Tryptase Stimulates the Synthesis of Type I Collagen in Human Lung Fibroblasts, J. Clin. Invest., Vol. 99, Number 6, March 1997, pages 1313-1321	
		CAUGHEY, G., et al., Substance P and Vasoactive Intestinal Peptide Degradation by Mast Cell Tryptase and Chymase, The Journal of Pharmacology and Experimental Therapeutics, (1988), Vol. 244, No. 1, pages 133-137	
		FRANCONI, G., et al. et al., Mast Cell Tryptase and Chymase Reverse Airway Smooth Muscle Relaxation Induced by Vasoactive Intestinal Peptide in the Ferret, The Journal of Pharmacology and Experimental Therapeutics, (1989), Vol. 248, No. 3, pages 947-951	
		HASEBE, et al., Photochemical generation of aliphatic radicals from benzophenone oxime esters: simple synthesis of alkylbenzenes and alkylpyridines, CAS Abstr. 106:119639-1987:119639, Hasebe et al, Tetr. Lett 27/28,3239-42(1986)	
		HIGUCHI, T, et al., Pro-drugs as Novel Drug Delivery Systems, ACS Symposium Series, Vol. 14	
		HOLST, et al., Antithrombotic Effect of Recombinant Truncated Tissue Factor Pathway Inhibitor (TFPI 1-181) in Experimental Venous Thrombosis- A Comparison with Low Molecular Weight Heparin, Thrombosis and Haemostasis, 71 (2) 214-219 (1994)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/616,141
		Filing Date	07/08/2003
		First Named Inventor	PAULS, et al.
		Group Art Unit	1623
		Examiner Name	JOHNSEN, Jason H.
		Attorney Docket Number	USA3676 - US - CNT
Sheet	3	of	4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		IRANI, et al., Human Conjunctival Mast Cells: Distribution of MCT and MCTC in Vernal Conjunctivitis and Giant Papillary Conjunctivitis, Journal of Allergy and Clinical Immunology, Volume 86, Number 1 pages 34-40	
		JARVIKALLIO, A, et al., Quantitative Analysis of Tryptase- and Chymase-containing Mast Cells in Atopic Dermatitis and Nummular Eczema, British Journal of Dermatology 1997, Vol. 136, pages 871-877	
		JEZIOBSKA, M, et al., Mast Cell Distribution, Activation, and Phenotype in Atherosclerotic Lesions of Human Carotid Arteries, Journal of Pathology, Vol. 182, 1997, pages 115-122	
		KOMOTO, et al., Preparation of .alpha.-[(N-benzoylpiperidinyl) phenoxy] isobutyrate and analogs as hypolipemics, CAS Abstr. 122:81127-1995:58573, Komoto et al, CA 2110095/5/1994	
		KURZ, et al., Rat Model Of Arterial Thrombosis Induced By Ferric Chloride, Thrombosis Research 60: 269-280, 1990	
		MCEUEN, et al., Guinea Pig Lung Tryptase, Biochemical Pharmacology, Vol. 52, pp. 331-340, 1996	
		NAUKKARINEN, A, et al., Immunohistochemical Analysis of Sensory Nerves and Neuropeptides, and Their Contacts with Mast Cells in Developing and Mature Psoriatic Lesions, Archives of Dermatological Research Vol. 285, 1993 pages 341-346	
		ROCHE, E., et al., Bioreversible Carriers in Drug Design Theory and Application, American Pharmaceutical Association and Pergamon Press, 1987	
		RUOSS, Stephen J, et al., Mast Cell Tryptase Is a Mitogen for Cultured Fibroblasts, J. Clin. Invest., Vol. 88, August 1991, pages 493-499	
		SCHWARTZ, L., et al., The a Form of Human Tryptase Is the Predominant Type Present in Blood at Baseline in Normal Subjects and Is Elevated in Those with Systemic Mastocytosis, The Journal of Clinical Investigation, Vol. 96, December 1995, pages 2702-2710	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-98)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	10/616,141
Filing Date	07/08/2003
First Named Inventor	PAULS, et al.
Group Art Unit	1623
Examiner Name	JOHNSEN, Jason H.
Attorney Docket Number	USA3676 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SEKIZAWA, K., et al., Mast Cell Trypsin Causes Airway Smooth Muscle Hyperresponsiveness in Dogs, J. Clin. Invest., Vol. 83, January 1989, pages 175-179	
		STEINHOFF, M., et al., Agonists of Proteinase-activated Receptor 2 Induce Inflammation by a Neurogenic Mechanism, Nature Medicine, Vol. 6, Number 2, February 2000, pages 151-158	
		TAM, et al., Degradation of Airway Neuropeptides by Human Lung Trypsin, Am. J. Respir. Cell Mol. Biol. Vol. 3, 1990, pages 27-32	
		TETLOW, L., et al., Distribution, Activation and Trypsin/Chymase Phenotype of Mast Cells in the Rheumatoid Lesion, Annals of the Rheumatic Diseases 1995; Vol. 54, pages 549-555	
		WILSON, S J., et al., Inflammatory Mediators in Naturally Occurring Rhinitis, Clinical and Experimental Allergy, 1998, Vol. 28, pages 220-227	
		ZHANG, M., et al., Mast Cell Trypsin and Asthma, Mediators of Inflammation, Vol. 6, 1997, pages 311-317	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
PAULS, et al.

Examiner: JOHNSON, Jason H.

Art Unit: 1623

RECEIVED
CENTRAL FAX CENTER

Application No.: 10/616,141

FEB 06 2006

Filed: 07/08/2003

Title: 1-AROYL-PIPERIDINYL BENZAMIDINES

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or being facsimile transmitted to the USPTO, on the date indicated below.

2-6-06
Date of Deposit
Signature *Red*

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☐ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☒ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,

February 6, 2006


Julie Anne Knight, Reg. No. 48,867
Attorney/Agent for Applicant


sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626
sanofi-aventis Docket No. USA3676 US CNT


PTO/SB/21 (09-04)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/616,141	RECEIVED CENTRAL FAX CENTER FEB 06 2006
	Filing Date	July 08, 2003	
	First Named Inventor	Heinz PAULS, et al.	
	Art Unit	1624	
	Examiner Name	JOHNSEN, Jason H.	
Total Number of Pages in This Submission	9	Attorney Docket Number	USA3676 US CNT

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">See remarks below</div>
Remarks 1. Communication 2. Corrected IDS 3. Copy of previously submitted Transmittal Fee Sheet for IDS 4. Copy of previously submitted 1449		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Julie Anne KNIGHT		
Date	February 06, 2006	Reg. No.	48,867

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300; Total No. of Pages Transmitted: 9)			
Signature			
Typed or printed name	Paul Irvine	Date	February 06, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT
Docket No: USA3676 US CNTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

CENTRAL FAX CENTER

FEB 06 2006

In re Application of
Heinz Pauls et al.


Examiner: Jason H. Johnson

Art Unit: 1623

Application No.: 10/616,141

Filed: July 8, 2003

Title: 1-Aroyl-Piperidinyl Benzamindines

Certificate of Mailing or Transmission	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.	
Date of Deposit	2-6-06
Printed Name of Person Signing Certificate	PAUL H. WINE
Signature	

COMMUNICATIONCommissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450


Dear Sir,

This Communication is submitted further to Applicant's Information Disclosure Statement (IDS) and Form 1449 filed February 3, 2006. Applicants note that page 2 of the IDS had two errors. 1) the IDS inadvertently included a "concise explanation" for a reference entitled "Rote Liste". Such reference is not cited in the instant IDS; and 2) the incorrect Docket Number was cited at the bottom of that same page. For purposes of clarity, Applicants concurrently resubmit the IDS in its corrected form herewith. Accordingly, Applicants request that this corrected IDS replace the previous version submitted on February 3, 2006. A copy of the originally submitted Form 1449 is also included herein.

A copy of the originally submitted "Transmittal" fee sheet is included herewith. Applicants believe that no additional fee is due. The Commissioner is hereby authorized, however, to charge any additional fees that may be deemed necessary to Deposit Account No. 18-1982 in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,

Date: February 6, 2006


Julie Anne Knight, Reg. No. 48,867
Attorney for ApplicantSanofi-aventis, U.S. Patents
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3679
Telefax (908) 231-2626
Sanofi-aventis Docket No. USA3676 US NP

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.